Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde
E O
EO
Department of Surgery, Leicester General Hospital, University of Leicester, United Kingdom.
Feehally
J
J
Scriven
S D
SD
Veitch
P S
PS
Bell
P R
PR
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004351:Drug Resistance; D006084:Graft Rejection / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone